[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100413423":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":36,"responsibleParty":54,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":10,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":10,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patient with MT",null,"Patients indicated for mechanical thrombectomy and benefiting from the procedure",[13],"Other: Prospective patient",{"label":15,"type":10,"description":16,"interventionNames":17},"Patient without MT","Patients indicated for mechanical thrombectomy but not benefiting from the intervention due to clinical improvement (patients responding to thrombolysis)",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"OTHER","Prospective patient","The immuno-inflammatory and thrombo-inflammatory profiles will be evaluated at inclusion, and at 24 hours +\u002F- 12 hours of the reperfusion treatment.",[9,15],[25],{"name":26,"affiliation":5,"role":27},"Benjamin Maier, MD","PRINCIPAL_INVESTIGATOR",[29,33],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","0148036556","bmaier@for.paris",{"name":34,"role":30,"phone":31,"phoneExt":10,"email":35},"Amélie Yavchitz, MD","ayavchitz@for.paris",[37],{"facility":38,"status":39,"city":40,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Hôpital Fondation Adolphe de Rothschild","RECRUITING","Paris","75019","France","FR",{"type":45,"coordinates":46},"Point",[47,48],2.3488,48.85341,{"lat":48,"lon":47},[51],{"name":52,"role":30,"phone":53,"phoneExt":10,"email":35},"Amélie YAVCHITZ, MD, PhD","+33 1 48 03 64 54",{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100413423","immunological-response-assessment-after-acute-ischemic-stroke-treated-with-endovascular-therapy-impress-100413423",false,"NCT04663399","IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy (IMPRESS)","IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy","IMPRESS","Inclusion Criteria:\n\n* Patient with an acute ischemic stroke for which treatment with mechanical thrombectomy is indicated, whether or not thrombectomy is performed,\n* Having received informed information about the study and having signed a consent to participate in the study (if this is not possible: information and consent of the trusted support person or family member if present; emergency inclusion if absent);\n* Affiliated or beneficiary of a social security scheme or equivalent.\n\nNon inclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Patient benefiting from a legal protection measure\n\nExclusion Criteria:\n\nNone.","ALL","18 Years",{"count":67,"type":68},1200,"ESTIMATED","OBSERVATIONAL","IMPRESS study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the first 24\u002F36 hours of treatment of patients suffering from AIC treated with TM, and to study the possible impact of these profiles on the functional prognosis at 3 and 12 months of AIC treatment.",[72,73],"Ischemic Stroke","Thrombectomy","2026-01-21",{"date":76,"type":77},"2026-01-23","ACTUAL",{"date":79,"type":77},"2023-02-23",{"date":81,"type":68},"2028-05-23",{"name":5,"class":6},1]